Recent advances in cytochrome c biosensing technologies

Abstract

This review is an attempt, for the first time, to describe advancements in sensing technology for cytochrome c (cyt c) detection, at point-of-care (POC) application. Cyt c, a heme containing metalloprotein is located in the intermembrane space of mitochondria and released into bloodstream during pathological conditions. The release of cyt c from mitochondria is a key initiative step in the activation of cell death pathways. Circulating cyt c levels represents a novel in-vivo marker of mitochondrial injury after resuscitation from heart failure and chemotherapy. Thus, cyt c detection is not only serving as an apoptosis biomarker, but also is of great importance to understand certain diseases at cellular level. Various existing techniques such as enzyme-linked immunosorbent assays (ELISA), Western blot, high performance liquid chromatography (HPLC), spectrophotometry and flow cytometry have been used to estimate cyt c. However, the implementation of these techniques at POC application is limited due to longer analysis time, expensive instruments and expertise needed for operation. To overcome these challenges, significant efforts are being made to develop electrochemical biosensing technologies for fast, accurate, selective, and sensitive detection of cyt c. Presented review describes the cutting edge technologies available in the laboratories to detect cyt c. The recent advancements in designing and development of electrochemical cyt c biosensors for the quantification of cyt c are also discussed. This review also highlights the POC cyt c biosensors developed recently, that would prove of interest to biologist and therapist to get real time informatics needed to evaluate death process, diseases progression, therapeutics and processes related with mitochondrial injury.

Real‐Time Cellular Cytochrome C Monitoring through an Optical Microfiber: Enabled by a Silver‐Decorated Graphene Nanointerface

“…In the apoptosis, cyt c releases from mitochondria, and then releases from cells as the cells break down. Its release is an essential signal of the initial progression of programmed cell death—apoptosis . In clinical disease diagnosis, once pathological conditions are triggered by cardiac failure, DNA damage, cytoskeleton disruption, or invasion from outside cells, the cyt c in mitochondria can be released into the bloodstream via permeabilization of injured mitochondria .…”

Astragalus polysaccharide, a component of traditional Chinese medicine, inhibits muscle cell atrophy (cachexia) in an in vivo and in vitro rat model of chronic renal failure by activating the ubiquitin-proteasome pathway

“…Protein lysates (30 µg) were then separated on a 10% SDS-PAGE gel followed by transfer to nitrocellulose membranes (Bio-Rad Laboratories, Inc.). Western blot analysis was performed according to a standard protocol (18) using primary antibodies against atrogin-1 (cat. no.…”

Epilepsy Seizure Detection and Prediction Based on DeviceHive

“…The problem of present epilepsy control products involves inappropriate follow-up on the number of seizures, the effectiveness of anti-epileptic drugs, and real-time analysis of changes in the patient body [22]. The advancements in nano-biotechnology have made the real-time analysis of epileptic patients possible, using wearable devices with advanced nano-enabled sensors [30][31][32][33]. In this review paper, the main focus is predestined on the existing IoT related work, appropriate biosensor and nanotechnology inference in the field of seizure prediction and detection.…”

“…[25] Many unmet needs are discussed as similar as addressing the burden of epilepsy. [30] This work presented an intelligent method for preprocessing in neurological disorders. The work was related to obtain more accurate results by removing artifacts of vital signals.…”